InDex's topical ulcerative colitis drug hits goal in phase 2b

InDex Pharmaceuticals CEO Peter Zerhouni (InDex Pharmaceuticals)

A phase 2b trial of InDex Pharmaceuticals’ ulcerative colitis drug has met its primary endpoint. The trial linked use of the highest dose of the topical TLR9 agonist to a 15% improvement in the clinical remission rate over placebo.

InDex enrolled 213 patients with left-sided moderate to severe active ulcerative colitis in the trial. To participate in the dose optimization trial, patients had to have tried oral 5-ASA medications, glucocorticosteroids and either immunomodulators or TNF-alpha inhibitors such as Johnson & Johnson’s Remicade without success.

In this refractory population, 21.4% of patients who received two 250 mg doses of cobitolimod via topical rectal administration were in clinical remission six weeks after starting treatment. The rate in the placebo cohort was 6.8%, resulting in the trial hitting its primary endpoint with a p value that came in just under the 0.05 threshold.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Lower doses of cobitolimod were less effective, achieving clinical remission rates ranging from 4.7% to 12.5%, but the results nonetheless emboldened InDex to talk up the prospects of the drug ahead of further studies. 

“With an outstanding combination of efficacy and safety, cobitolimod is set to take a leading position within the field. We will now advance cobitolimod towards phase 3 and in parallel evaluate the best route to commercialisation,” InDex CEO Peter Zerhouni said in a statement.

InDex first took cobitolimod, then known as Kappaproct, into phase 3 late in 2011. Almirall licensed the European rights to the drug in a deal potentially worth more than €100 million ($111 million) in 2014, only to terminate the agreement a little more than one year later.

The termination followed the delivery of data from the phase 3 trial that began in 2011. The study missed its primary endpoint of clinical remission at 12 weeks but delivered enough encouraging signs against secondary endpoints for InDex to run another trial. Positives included the higher rate of symptomatic remission seen in the treatment group in the fourth week of the study.

Suggested Articles

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics has added another $110 million to its coffers.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.